CLEC4A Protein, Mouse, Recombinant (hFc)

Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 418.00
500 μg	5 days	$ 1,670.00
1 mg	5 days	$ 2,800.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 418.00

500 μg

5 days

$ 1,670.00

1 mg

5 days

$ 2,800.00

Description

Species	Mouse
Expression System	HEK293
Tag	C-hFc
Accession Number	Q9QZ15
Synonyms	HDCGC13P, Clec4a2, DCIR, CD367, CLECSF6, DCIRLLIR, LLIR, CLEC4A, DDB27
Construction	Recombinant Mouse CLEC4A/DCIR Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Gln70-Leu238.[Accession \|Q9QZ15]
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	The protein has a predicted MW of 46.3 kDa. Due to glycosylation, the protein migrates to 60-65 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Stability & Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy.